Recursion inks second deal this week, this one with Roche

Deal hungry Recursion Pharmaceuticals (Nasdaq: RXRX) signed a second deal this week, entering into a collaboration with Swiss giant Roche (ROG: SIX) and its Genentech subsidiary, to more rapidly identify novel targets and advance medicines in key areas of neuroscience as well as in an oncology indication.

The news pushed Recursion’s shares up 8.3% to $20.01 by mid-morning, adding to the boost the stock had yesterday on the deal with Germany’s Bayer (BAYN: DE).

The collaboration will leverage the US digital biotech’s Recursion Operating System (OS), an integrated, multi-faceted system for generating, analyzing and deriving insight from massive proprietary biological and chemical datasets. The OS, which brings together wet-lab and dry-lab biology at scale to further industrialize and digitize drug discovery, will be deployed to phenomically capture chemical and genetic perturbations in neuroscience-related cell types and select cancer cell lines.